Refine by
Tumor Targeting Articles & Analysis: Older
55 news found
Specifically, it covers Cartherics’ chimeric antigen receptor (CAR) targeting tumor-associated glycoprotein-72 (TAG-72), along with T cells bearing the TAG-72 CAR. ...
Cancer Vaccine Development Based on pMHC Cancer vaccines to enhance the immune response, target tumor-specific mutations not present in normal tissues, and eradicate tumors. Vaccine Development Based on VLPs with MHC Complex To demonstrate and deliver specific tumor-associated MHC complex antigens and create more scalable and ...
About CTH-001 CTH-001 is a Cartherics’ proprietary product candidate based on autologous (i.e., patient-derived) chimeric antigen receptor (CAR)-T cells targeting tumor associated glycoprotein 72 (TAG-72). Cartherics’ researchers identified that TAG-72 is present on the aberrant T cells associated with CTCL but is essentially absent from normal T ...
More importantly, NIR quantum dots consist of stronger penetration capability in tumor-targeted imaging, which can effectively avoid tissue absorption and autofluorescence. ...
Tavros to receive $17.5M upfront, up to $430.5M in milestone payments for initial four programs, and certain royalties over agreement term / Vividion will have rights to opt-in to up to five more targets for up to $482M in additional payments /Partnership to define novel drug targets and biomarkers, in addition to positioning existing compounds Tavros ...
ByBayer AG
Structurally, PDC mainly contains three elements—cytotoxin, linker, and targeted peptide, in which a specific peptide sequence covalently connects with the cytotoxin through a decomposable linker. PDCs can be used as tumor-targeting vectors, imaging agents, and diagnostic tools. They have a wide range of indications, involving brain ...
TyroSphere beads are bioresorbable embolic microspheres designed to treat hypervascular tumors. TyroSphere beads uniquely offer both the advantage of safe degradation/resorption and the option of being visible under standard x-ray to aid in precise delivery to the targeted tumor. ...
The first clinicalfindingshave shown that BAT-90makes it possible to treat onlythe area where the tumour is located, while avoiding the surrounding tissues, so as to combine treatmentefficacy and patient safety BetaGlue Technologieshasenrolledthe first patientin a clinical trialwithBAT-90, the company’s cancer radiotherapy platform. The first clinical findings have shown thatBAT-90 ...
Fin Posillipo (Petrone Group], Kairos Partners SGR, LIFTT, Neva Sgr (Intesa Sanpaoh Group), Profequycapital and Romedjoined the share capital Innogest Capital and Panakes Partners reinvest The financing will give BetaGlue Technologies the ability to further develop its advanced radiotherapy platform, BAT-90, and accelerate access to the Safe-Biopsy Device market, thus opening a new chapter in ...
The first clinical results have shown that BAT-90 innovative radiotherapy platform makes it possible to treat only the area where the tumour is located, while avoiding the surrounding tissues, so as to combine treatment efficacy and patient safety CEO/CMO, Dr. Antonino Amato, said: "The confirmation in this first patient of the previous findings from the pre-clinical studies with BAT-90 opens ...
” The SAB members are leaders in a broad range of areas relevant to Affimed’s approach to developing cancer therapies including immuno-oncology, the biology of NK cells, lymphomas, leukemias, and solid tumors. To learn more about the members of the new Scientific Advisory Board, please visit the “About Us” section of Affimed’s website at ...
AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational status Study demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-negative healthy bone marrow progenitors In vivo studies of an ...
Preclinical Programs AFM28 (CD123/CD16A) AFM28 is a bispecific, tetravalent ICE® that targets CD16A on NK cells and macrophages, and CD123 on leukemic blasts and leukemic stem cells that are prevalent in acute myeloid leukemia (AML). ...
The Company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, ...
The combination of AFM24 and PD-L1 inhibitor, atezolizumab, may represent a promising new treatment modality, enhancing both the innate and adaptive immune responses to target EGFR+ tumor cells. An ongoing phase 1/2a open-label, non-randomized, multicenter, dose escalation (phase 1) and dose expansion (phase 2) study was initiated in November 2021 to evaluate ...
The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, ...
The Company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, ...
The poster also demonstrated the feasibility of cryopreserving AFM28 pre-complexed with NK cells whilst maintaining anti-tumor activity suggesting the promise for an off-the-shelf therapy targeting leukemic blasts and leukemic stem cells in patients with AML and MDS. Poster details: Title: Analysis of the Longitudinal Effects of AFM24, a CD16A/Epidermal Growth ...
For more information, please visit www.interx.dev About NeoTX NeoTX is a clinical-stage company developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and ...
ByInterX
“Specifically, the ability of our technology to target tumor self-antigens and induce a potent T cell response that leads to tumor regression is important as we prepare to file an IND for our HB-300 program in prostate cancer in the third quarter. ...